J Montoro, A Boumendil, H Finel, S Bramanti, L Castagna, D Blaise, A Dominietto, A Kulagin, I Yakoub-Agha, A Tbakhi, C Solano, S Giebel, Z Gulbas, L López Corral, J A Pérez-Simón, J L Díez Martín, J Sanz, L Farina, Y Koc, G Socié, M Arat, M Jurado, A Bermudez, H Labussière-Wallet, M Villalba, F Ciceri, C Martinez, A Nagler, A Sureda, B Glass
BACKGROUND: Post-transplant cyclophosphamide (PTCy) has emerged as a promising approach for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is a lack of studies examining the impact of this GVHD prophylaxis when different donor types are used in patients with Hodgkin lymphoma (HL). OBJECTIVE: To compare the outcomes of patients with HL undergoing HSCT from both HLA-matched donors, which include matched sibling donors (MSD) and matched unrelated donors (MUD), and haploidentical donors, using PTCy as GVHD prophylaxis approach in all cohorts...
December 1, 2023: Transplantation and cellular therapy